SecBot SecBot
SECBOTREPLAY Home › Report › FOLD

FOLD · Amicus Therapeutics completed its acquisition by BioMarin…

AMICUS THERAPEUTICS, INC. · 8-K filed Apr 27, 2026 at 11:43 ET

At the news

NEUTRALIMPACT 9/10

8-K filed Apr 27, 2026 at 11:43 ET

Amicus Therapeutics completed its acquisition by BioMarin Pharmaceutical, resulting in a change of control, delisting from Nasdaq, and termination of its credit agreement. All directors and executive officers resigned, with BioMarin appointing new leadership. Shareholders received $14.50 per share in cash.

  • Merger with BioMarin Pharmaceutical completed on April 27, 2026, with Amicus becoming a wholly owned subsidiary.
  • Shareholders received $14.50 per share in cash as merger consideration.
  • Company common stock to be delisted from Nasdaq; Form 25 filed for deregistration.
  • All nine directors and five executive officers resigned; BioMarin appointees took over leadership roles.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access